Feature

Metabolic syndrome risk in patients prescribed atypical antipsychotics: As comorbidities multiply, the debate over monitoring responsibilities continues.

Whitney McKnight

  • Psychiatric Annals
  • July 2011 - Volume 41 · Issue 7: 347-349
  • DOI: 10.3928/00485713-20110627-05
Rights and Permissions

Abstract

In 2003, the FDA issued a warning for second-generation antipsychotics, including olanzapine and risperidone, among others, citing an increased risk for diabetes and hyperglycemia. The FDA stated that glucose levels should be monitored in patients with diabetes, at risk for diabetes or with symptoms of hyperglycemia. Concurrently, the American Diabetes Association and American Psychiatric Association recommended glucose and lipid testing for all patients started on second-generation antipsychotics.
AUTHORS

(additional reporting by Angelo Milone)

doi: 10.3928/00485713-20110627-05

Healio is intended for health care provider use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will Healio be used for medical advice to patients.

[X]